Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly japanese woman with severe osteoporosis

Clinical Drug Investigation

Volumn 32, Issue 8, 2012, Pages 547-553

  Iwamoto, Jun ^a   Yago, Kaori ^b   Sato, Yoshihiro ^c   Matsumoto, Hideo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b International University of Health and Welfare Mita Hospital   (Japan)

^c Mitate Hospital   (Japan)

Author keywords

bisphosphonate; elderly; osteonecrosis of the jaw; osteoporosis; teriparatide

Indexed keywords

AMOXICILLIN; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; PIPERACILLIN; RISEDRONIC ACID; SODIUM CHLORIDE;

AGED; ARTICLE; BODY HEIGHT; BODY MASS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; DEBRIDEMENT; DISEASE MARKER; DISEASE SEVERITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GASTRECTOMY; GRAM POSITIVE INFECTION; HEADACHE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; JAPANESE; JAW OSTEONECROSIS; JAW PAIN; NAUSEA; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH ULCER; VERTIGO;

AGED; BONE DENSITY; DIPHOSPHONATES; FEMALE; HUMANS; JAPAN; JAW DISEASES; OSTEOPOROSIS; TERIPARATIDE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863594102     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/bf03261908     Document Type: Article

References (28)

1. Cavanna L, Bertè R, Arcari A, et al. Osteonecrosis of the jaw: A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates.Report of five cases and review of the literature. Eur J Int Med 2007; 18: 417-422 (Pubitemid 47211940)
2. Melo MD, Obeld G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early detection. J Am Dent Assoc 2005; 136: 1675-1681 (Pubitemid 41810029)
3. Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18: 1363-1370 (Pubitemid 47389465)
4. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006; 24: 945-952 (Pubitemid 46638849)
5. Harper RP, Fung E.Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65: 573-580 (Pubitemid 46343587)
6. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol 2009; 36: 1835-1837
7. Cheung A, Seeman E. Teriparatide therapy for alendronateassociated osteonecrosis of the jaw. N Engl J Med 2010; 363: 2473-2474
8. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010; 363: 2396-2405
9. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441 (Pubitemid 32402100)
10. Lilly USA. Highlights of prescribing information [online]. Available from URL: Http://pi.lilly.com/us/forteo-pi.pdf [Accessed 2012 Apr 1]
11. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703 (Pubitemid 41127277)
12. Shiraki M, Fukunaga M, Kushida K, et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis. Osteoporos Int 2003; 14: 225-234
13. Kishimoto H, Fukunaga M, Kushida K, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 2006; 24: 405-413 (Pubitemid 44306178)
14. Yoneda T, Hagino H, Sugimoto T, et al. Bisphosphonaterelated osteonecrosis of the jaw: Position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010; 28: 365-383
15. Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998; 16: 139-150 (Pubitemid 28411037)
16. Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: Year 2000 revision. J Bone Miner Metab 2001; 19: 331-337 (Pubitemid 33041725)
17. Orimo H. Japanese guideline for prevention and treatment of osteoporosis: ii. Diagnosis of osteoporosis [in Japanese]. Life Science 2011: Pp.16-17
18. Miyauchi A, Matsumoto T, Sugimoto T, et al. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010; 47: 493-502
19. Galluzzo S, SantiniD, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: An intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 2007; 11: 941-954 (Pubitemid 47054489)
20. Tsujimoto M, Chen P, Miyauchi A, et al. PINP as an aid for monitoring patients treated with teriparatide. Bone 2011; 48: 798-803
21. Lim SK, Kung AW, Sompongse S, et al. Vitamin D inadequacy in postmenopausal women in Eastern Asia. Curr Med Res Opin 2008; 24: 99-106 (Pubitemid 351160243)
22. Iwamoto J, Takeda T, Matsumoto H. Sunlight exposure is important for preventing hip fractures in patients with Alzheimer's disease, Parkinson's disease, or stroke. Acta Neurol Scand 2011. Epub.
23. Sato Y, Metoki N, Iwamoto J, et al. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients. Neurology 2003; 61: 338-342 (Pubitemid 36975962)
24. Sato Y, Iwamoto J, Kanoko T, et al. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: A randomized controlled trial. J Bone Miner Res 2005; 20: 1327-1333 (Pubitemid 41033516)
25. Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 22-26
26. Dawson-Hughes B, Chen P, Krege JH. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 2007; 92: 4630-4636 (Pubitemid 350223437)
27. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-2030 (Pubitemid 39390560)
28. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005; 20: 1507-1513 (Pubitemid 41243539)